Gilgamesh

Gilgamesh is a preclinical biotechnology company focused on serious mental health science. They are working on innovative new chemical entities (NCE’s), bringing together medicinal chemistry, neuroscience & neurobiology, drug development expertise, and intellectual property strategy.

Gilgamesh

The company is developing oral arylcyclohexylamine and next-generation psychedelics for mental health and other impairments such as Treatment-Resistant Depression (TRD), opiate use disorder (SUD), ADHD, and depression with cognitive impairment.

Gilgamesh has raised a total of $29.6 million in funding over 5 rounds. Their latest funding was raised on May 6th, 2021 from a Series A round.

“The next generation of central nervous system drugs inspired by psychedelic medicines”

Key staff

  • Johnathan Sporn – Founder & CEO
  • Andrew Kreugel – Co-founder & Head of Chemistry
  • Gerard Marek – CMO

Media

Company Information

Gilgamesh Website

Founded
August, 2019

Operational
Yes

Activities
B2B Biotech Drug Discovery

Explore more company info with a Tree membership

📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates

Explore memberships

Location

HQ / Office 113 University Pl #1019, New York, NY 10003, USA